Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide expert insights on practice changing data from IGCS 2021 presented for endometrial, ovarian, and cervical cancers regarding:
Medical Oncologist and Team Leader
Gynecology Translational Research Lab
Department of Medicine
Gustave Roussy Cancer Center
Gynecologic Oncology Department
Clinical Research Unit
Fondazione Policlinico Gemelli IRCCS
This program has been made available online.
Downloadable slideset updated with highlights of key gynecologic oncology studies presented at conferences throughout 2022, from Clinical Care Options (CCO)
Phase III MITO23: data on trabectedin vs investigator’s choice of chemotherapy in BRCA-mutant or BRCAness phenotype recurrent ovarian cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)
Overall survival data for intermittent or continuous relacorilant + nab-pac pac vs nab-pac alone in recurrent PROC, presented at ASCO 2022 and reported by Clinical Care Options (CCO)
Latest ATHENA-MONO data on first-line maintenance therapy with rucaparib in advanced ovarian cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)